Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer
This study is a single-arm, open, multi-center clinical study of nab-paclitaxel as the therapy ER+/HER2- recurrent metastatic breast cancer。
Breast Cancer
DRUG: nab-paclitaxel
Objective Response Rate (ORR), Defined as proportion of complete response and partial response according to RECIST 1.1 criteria., Estimated up to 1 year
Clinical benefit rate, Defined as proportion of complete response 、partial response and stable disease according to RECIST 1.1 criteria., CR+PR+SD≥8 weeks|Progression-Free Survival (PFS), Calculated from the time the study drug was first administered to the first confirmation of disease progression or death (whichever occurs first), Estimated up to 2 year
This study is a single-arm, open, multi-center clinical study of nab-paclitaxel as the therapy ER+/HER2- recurrent metastatic breast cancer。